CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
Jeffrey E. Lancet(Moffitt Cancer Center), Geoffrey L. Uy(Washington University in St. Louis), Laura F. Newell(Oregon Health & Science University), Tara L. Lin(University of Kansas Medical Center), Ellen K. Ritchie(Cornell University), Robert K. Stuart(Medical University of South Carolina), Stephen A. Strickland(Vanderbilt-Ingram Cancer Center), Donna E. Hogge(Leukemia & Lymphoma Society of Canada), Scott R. Solomon(Northside Hospital), Dale L. Bixby(University of Michigan–Ann Arbor), Jonathan E. Kolitz(Northwell Health), Gary J. Schiller(University of California, Los Angeles), Matthew J. Wieduwilt(University of Oklahoma), Daniel Ryan(University of Rochester), Stefan Faderl(Jazz Pharmaceuticals (United States)), Jörge E. Cortes(Augusta University Health)
Cited by 210
Abstract
Related Papers
No related papers found
Powered by citation graph analysis